Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Chenwei Tang
Institution:
Second Affiliated Hospital of Chongqing Medical University
Observed institutions:
Sun Yat-sen University,
Shanghai Jiao Tong University,
XinHua Hospital,
Sun Yat-sen Memorial Hospital,
Second Affiliated Hospital of Chongqing Medical University
ORCID:
0000-0001-5252-9414
Observed ORCID:
0000-0001-5252-9414
OpenAlex ID:
A5037941005
Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy
2024
·
Yonglin Hua
, Zhixian Sun
, et al.
·
Journal for ImmunoTherapy of Cancer
·
72
PDF
Identification of LSM Family Members as Novel Unfavorable Biomarkers in Hepatocellular Carcinoma
2022
·
Hongkai Zhuang
, Bo Chen
, et al.
·
Frontiers in Oncology
·
31
SLC39A1 Overexpression is Associated with Immune Infiltration in Hepatocellular Carcinoma and Promotes Its Malignant Progression
2022
·
Xiaowu Ma
, Hongkai Zhuang
, et al.
·
Journal of Hepatocellular Carcinoma
·
23
PDF
CircNUP54 promotes hepatocellular carcinoma progression via facilitating HuR cytoplasmic export and stabilizing BIRC3 mRNA
2024
·
Chenwei Tang
, Hongkai Zhuang
, et al.
·
Cell Death and Disease
·
22
PDF
Identification of a Novel Ferroptosis-Related Gene Signature for Predicting Prognosis and Responsiveness to Immunotherapy in Hepatocellular Carcinoma
2023
·
Qingbin Wang
, Bingkun Wang
, et al.
·
Journal of Hepatocellular Carcinoma
·
13
PDF
Lenvatinib inhibits cholangiocarcinoma progression by targeting the FGF19/PI3K/AKT signaling pathway
2024
·
Yingcheng Wei
, Lei Yang
, et al.
·
APOPTOSIS
·
6
AKR1B10 Drives Lenvatinib Resistance in Hepatocellular Carcinoma by Suppressing Ferroptosis via NQO1/GPX4 Axis
2026
·
Jiahao Jiang
, Bingkun Wang
, et al.
·
Journal of Gastroenterology and Hepatology
·
3
Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma
2025
·
Hongkai Zhuang
, Chenwei Tang
, et al.
·
Clinical Cancer Research
·
3
A novel risk score system based on immune subtypes for identifying optimal mRNA vaccination population in hepatocellular carcinoma
2024
·
Hongkai Zhuang
, Chenwei Tang
, et al.
·
Cellular Oncology
·
3
Identification of FOXP1 as a favorable prognostic biomarker and tumor suppressor in intrahepatic cholangiocarcinoma
2024
·
Chenwei Tang
, Hongkai Zhuang
, et al.
·
BMC Cancer
·
3
PDF
Prognostic stratification based on HIF-1α signaling for evaluating hypoxia status and immune landscape in hepatocellular carcinoma
2023
·
Hongkai Zhuang
, Zedan Zhang
, et al.
·
Journal Of Big Data
·
1
PDF
Supplementary Figure S5 from Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma
2025
·
Hongkai Zhuang
, Chenwei Tang
, et al.
PDF
Data from Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma
2025
·
Hongkai Zhuang
, Chenwei Tang
, et al.
Supplementary Figure S1 from Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma
2025
·
Hongkai Zhuang
, Chenwei Tang
, et al.
PDF
Supplementary Figure S2 from Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma
2025
·
Hongkai Zhuang
, Chenwei Tang
, et al.
PDF
Supplementary Figure S3 from Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma
2025
·
Hongkai Zhuang
, Chenwei Tang
, et al.
PDF
Supplementary Figure S4 from Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma
2025
·
Hongkai Zhuang
, Chenwei Tang
, et al.
PDF
Supplementary Table S3 from Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma
2025
·
Hongkai Zhuang
, Chenwei Tang
, et al.
Supplementary Table S1 from Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma
2025
·
Hongkai Zhuang
, Chenwei Tang
, et al.
Supplementary Table S2 from Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma
2025
·
Hongkai Zhuang
, Chenwei Tang
, et al.
Supplementary Table S4 from Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma
2025
·
Hongkai Zhuang
, Chenwei Tang
, et al.
Show more works
View as search
Works count:
21
Citation count:
180
H-index:
6
I10-index:
5
Year
Topic
Type